SenzaGen secures SEK 1.7m order from a new global biotech industry leader

SenzaGen has been selected to test substances for yet another new global customer within the biotech industry. The assignment is valued at SEK 1.7 million and includes non-animal tests for skin sensitization, utilizing SenzaGen’s highly performing test platform, GARD®skin. The tests will be conducted at the company's GLP-certified laboratories in Lund and at the subsidiary, VitroScreen, in Milan during the fourth quarter of 2023 and the first quarter of 2024.

The customer is a global leader in biotech with a significant presence and research in various chemical areas. Through this testing, they aim to investigate whether their new product candidates can cause allergic reactions on the skin.

"Through this order, we further broaden our portfolio with another world player choosing us to replace animal experiments with more ethical methods. The acquisition of VitroScreen has strengthened our position in skin sensitization and now opens up new opportunities in the market. With our combined product portfolio, we offer our customers a comprehensive testing solution, providing them with fast and reliable test results for evaluating product candidates," says Peter Nählstedt, President and CEO of SenzaGen.

The core of SenzaGen’s business revolves around innovative tests and services within non-animal toxicology and efficacy testing. These innovations are based on the company's extensive expertise in various technology areas, including genomics, machine learning, and human 3D tissue models. By offering unique and groundbreaking innovations that are better suited to reflect human biological reactions, SenzaGen is driving progress away from animal testing.